New antiviral therapies for hepatitis C.
Hepatitis C affects 170 million people worldwide and is the leading indication for liver transplantation. However, despite this high prevalence and burden of disease, current treatment regimens necessitate long durations of therapy, are often poorly tolerated and have suboptimal rates of sustained virologic response. Therefore, much attention has been directed at the development of new therapeutic agents against specific viral targets. This article reviews modifications of current therapies, outlines the viral life cycle and focuses on novel therapeutic agents currently being studied.
Gi Unit, Massachusetts General Hospital, Boston 02114, USA. jgoleary@partners.org
Jacqueline
J
O'Leary
Raymond T
RT
Chung
D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016174:Hepacivirus / Q000502:physiology; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use; D016031:Liver Transplantation
D000998:Antiviral Agents; D007155:Immunologic Factors; D007168:IMP Dehydrogenase